Loading…
Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature
To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN). A retrospective review of clinical files between January 1999 and December 2...
Saved in:
Published in: | Frontiers in medicine 2018-08, Vol.5, p.240-240 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23 |
---|---|
cites | cdi_FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23 |
container_end_page | 240 |
container_issue | |
container_start_page | 240 |
container_title | Frontiers in medicine |
container_volume | 5 |
creator | Tock, Stéphanie Jadoul, Pascale Squifflet, Jean-Luc Marbaix, Etienne Baurain, Jean-François Luyckx, Mathieu |
description | To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN).
A retrospective review of clinical files between January 1999 and December 2016.
University hospital.
Eighteen women younger than 41 years with grade 1 endometrial carcinoma (G1EC) and/or Endometrial intra-epithelial neoplasia (EIN).
All patients received GnRH agonist for 3 months after an endometrial resection combined with a laparoscopy to exclude concomitant ovarian tumor and/or other extra-uterine disease. The patient underwent a follow-up of 3 months interval with endometrial sampling by hysteroscopy.
The recurrence rate and the pregnancy rate after fertility sparing treatment.
We identified 9 patients with EIN (50%), 7 patients with G1EC (38.9%), 1 with combined histology (5.5%), and 1 with G2EC (5.5%). After a median follow-up of 40.7 months, 12 patients conserved their uterus (66.7%), and 8 (53.3%) patients were pregnant with a total of 14 pregnancies among those who tried to become pregnant. We observed a complete response rate in 12 patients (66.7%) but 3 of these patients relapsed (25%). We also found a stable disease in 6 patients (33.3%).
Compared with other fertility sparing treatments, GnRH agonist after surgery is an effective fertility-sparing strategy for women with EIN and/or G1EC. We recommend hysterectomy once a family has been completed even if the literature does not clearly lead to radical surgery. |
doi_str_mv | 10.3389/fmed.2018.00240 |
format | article |
fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_01e049bf6ed2474aa153cf0e4d4f874a</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_01e049bf6ed2474aa153cf0e4d4f874a</doaj_id><sourcerecordid>2103675073</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23</originalsourceid><addsrcrecordid>eNpVkk1vEzEQhlcIRKvSMzfkIweS-mPX9nJAiqL0QwoCpa3gZnl3ZzeuNnZqe4Py3_hxeJNStSePxzPPa4_fLPtI8JQxWV60G2imFBM5xZjm-E12SmnJJ7KQv9--iE-y8xAeMMaE0SIn7H12wjAlhHBxmv29BB9Nb-Ie3W61N7ZDdx503ICNyFj0U0eTwoB-mbhGC-37VBh1B2hhG7eB6I3u0VzbGvwXdB9GgEZzt6mMTa3OItei28F34PdI2wZd2dU1mnXOmhC_ohn67qyrk4I3NVolnAtbqKPZQZIZmmPPCnYG_oykuAa0NBG8joOHD9m7VvcBzp_Ws-z-cnE3v54sf1zdzGfLSZ0XZZxUJRRNK4jkNK8oF4TWLW6LShYgpBAl1KJteSkFL3guxzxpGMUFIayQlabsLLs5chunH9TWm432e-W0UYeE853SaYp1DwoTwHlZtRwamotca1KwpAZ5k7cy7RPr25G1Har0f4en6_4V9PWJNWvVuZ3ihJRcygT4_ATw7nGAENXGhBr6XltwQ1CUYMZFgQVLpRfH0jqNNXhon2UIVqOF1GghNVpIHSyUOj69vN1z_X_DsH9QG8Vi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2103675073</pqid></control><display><type>article</type><title>Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature</title><source>PubMed Central Free</source><creator>Tock, Stéphanie ; Jadoul, Pascale ; Squifflet, Jean-Luc ; Marbaix, Etienne ; Baurain, Jean-François ; Luyckx, Mathieu</creator><creatorcontrib>Tock, Stéphanie ; Jadoul, Pascale ; Squifflet, Jean-Luc ; Marbaix, Etienne ; Baurain, Jean-François ; Luyckx, Mathieu</creatorcontrib><description>To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN).
A retrospective review of clinical files between January 1999 and December 2016.
University hospital.
Eighteen women younger than 41 years with grade 1 endometrial carcinoma (G1EC) and/or Endometrial intra-epithelial neoplasia (EIN).
All patients received GnRH agonist for 3 months after an endometrial resection combined with a laparoscopy to exclude concomitant ovarian tumor and/or other extra-uterine disease. The patient underwent a follow-up of 3 months interval with endometrial sampling by hysteroscopy.
The recurrence rate and the pregnancy rate after fertility sparing treatment.
We identified 9 patients with EIN (50%), 7 patients with G1EC (38.9%), 1 with combined histology (5.5%), and 1 with G2EC (5.5%). After a median follow-up of 40.7 months, 12 patients conserved their uterus (66.7%), and 8 (53.3%) patients were pregnant with a total of 14 pregnancies among those who tried to become pregnant. We observed a complete response rate in 12 patients (66.7%) but 3 of these patients relapsed (25%). We also found a stable disease in 6 patients (33.3%).
Compared with other fertility sparing treatments, GnRH agonist after surgery is an effective fertility-sparing strategy for women with EIN and/or G1EC. We recommend hysterectomy once a family has been completed even if the literature does not clearly lead to radical surgery.</description><identifier>ISSN: 2296-858X</identifier><identifier>EISSN: 2296-858X</identifier><identifier>DOI: 10.3389/fmed.2018.00240</identifier><identifier>PMID: 30211167</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>atypical endometrial hyperplasia ; conservative treatment ; endometrial adenocarcinoma ; fertility-sparing ; GnRH agonist ; Medicine</subject><ispartof>Frontiers in medicine, 2018-08, Vol.5, p.240-240</ispartof><rights>Copyright © 2018 Tock, Jadoul, Squifflet, Marbaix, Baurain and Luyckx. 2018 Tock, Jadoul, Squifflet, Marbaix, Baurain and Luyckx</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23</citedby><cites>FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119688/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119688/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30211167$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tock, Stéphanie</creatorcontrib><creatorcontrib>Jadoul, Pascale</creatorcontrib><creatorcontrib>Squifflet, Jean-Luc</creatorcontrib><creatorcontrib>Marbaix, Etienne</creatorcontrib><creatorcontrib>Baurain, Jean-François</creatorcontrib><creatorcontrib>Luyckx, Mathieu</creatorcontrib><title>Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature</title><title>Frontiers in medicine</title><addtitle>Front Med (Lausanne)</addtitle><description>To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN).
A retrospective review of clinical files between January 1999 and December 2016.
University hospital.
Eighteen women younger than 41 years with grade 1 endometrial carcinoma (G1EC) and/or Endometrial intra-epithelial neoplasia (EIN).
All patients received GnRH agonist for 3 months after an endometrial resection combined with a laparoscopy to exclude concomitant ovarian tumor and/or other extra-uterine disease. The patient underwent a follow-up of 3 months interval with endometrial sampling by hysteroscopy.
The recurrence rate and the pregnancy rate after fertility sparing treatment.
We identified 9 patients with EIN (50%), 7 patients with G1EC (38.9%), 1 with combined histology (5.5%), and 1 with G2EC (5.5%). After a median follow-up of 40.7 months, 12 patients conserved their uterus (66.7%), and 8 (53.3%) patients were pregnant with a total of 14 pregnancies among those who tried to become pregnant. We observed a complete response rate in 12 patients (66.7%) but 3 of these patients relapsed (25%). We also found a stable disease in 6 patients (33.3%).
Compared with other fertility sparing treatments, GnRH agonist after surgery is an effective fertility-sparing strategy for women with EIN and/or G1EC. We recommend hysterectomy once a family has been completed even if the literature does not clearly lead to radical surgery.</description><subject>atypical endometrial hyperplasia</subject><subject>conservative treatment</subject><subject>endometrial adenocarcinoma</subject><subject>fertility-sparing</subject><subject>GnRH agonist</subject><subject>Medicine</subject><issn>2296-858X</issn><issn>2296-858X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkk1vEzEQhlcIRKvSMzfkIweS-mPX9nJAiqL0QwoCpa3gZnl3ZzeuNnZqe4Py3_hxeJNStSePxzPPa4_fLPtI8JQxWV60G2imFBM5xZjm-E12SmnJJ7KQv9--iE-y8xAeMMaE0SIn7H12wjAlhHBxmv29BB9Nb-Ie3W61N7ZDdx503ICNyFj0U0eTwoB-mbhGC-37VBh1B2hhG7eB6I3u0VzbGvwXdB9GgEZzt6mMTa3OItei28F34PdI2wZd2dU1mnXOmhC_ohn67qyrk4I3NVolnAtbqKPZQZIZmmPPCnYG_oykuAa0NBG8joOHD9m7VvcBzp_Ws-z-cnE3v54sf1zdzGfLSZ0XZZxUJRRNK4jkNK8oF4TWLW6LShYgpBAl1KJteSkFL3guxzxpGMUFIayQlabsLLs5chunH9TWm432e-W0UYeE853SaYp1DwoTwHlZtRwamotca1KwpAZ5k7cy7RPr25G1Har0f4en6_4V9PWJNWvVuZ3ihJRcygT4_ATw7nGAENXGhBr6XltwQ1CUYMZFgQVLpRfH0jqNNXhon2UIVqOF1GghNVpIHSyUOj69vN1z_X_DsH9QG8Vi</recordid><startdate>20180827</startdate><enddate>20180827</enddate><creator>Tock, Stéphanie</creator><creator>Jadoul, Pascale</creator><creator>Squifflet, Jean-Luc</creator><creator>Marbaix, Etienne</creator><creator>Baurain, Jean-François</creator><creator>Luyckx, Mathieu</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180827</creationdate><title>Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature</title><author>Tock, Stéphanie ; Jadoul, Pascale ; Squifflet, Jean-Luc ; Marbaix, Etienne ; Baurain, Jean-François ; Luyckx, Mathieu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>atypical endometrial hyperplasia</topic><topic>conservative treatment</topic><topic>endometrial adenocarcinoma</topic><topic>fertility-sparing</topic><topic>GnRH agonist</topic><topic>Medicine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tock, Stéphanie</creatorcontrib><creatorcontrib>Jadoul, Pascale</creatorcontrib><creatorcontrib>Squifflet, Jean-Luc</creatorcontrib><creatorcontrib>Marbaix, Etienne</creatorcontrib><creatorcontrib>Baurain, Jean-François</creatorcontrib><creatorcontrib>Luyckx, Mathieu</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tock, Stéphanie</au><au>Jadoul, Pascale</au><au>Squifflet, Jean-Luc</au><au>Marbaix, Etienne</au><au>Baurain, Jean-François</au><au>Luyckx, Mathieu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature</atitle><jtitle>Frontiers in medicine</jtitle><addtitle>Front Med (Lausanne)</addtitle><date>2018-08-27</date><risdate>2018</risdate><volume>5</volume><spage>240</spage><epage>240</epage><pages>240-240</pages><issn>2296-858X</issn><eissn>2296-858X</eissn><abstract>To evaluate the efficacy and safety of gonadotropin-releasing hormone (GnRH) agonist after endometrial resection in women suffering early stage endometrial carcinoma (EC) and/or endometrial intra-epithelial neoplasia (EIN).
A retrospective review of clinical files between January 1999 and December 2016.
University hospital.
Eighteen women younger than 41 years with grade 1 endometrial carcinoma (G1EC) and/or Endometrial intra-epithelial neoplasia (EIN).
All patients received GnRH agonist for 3 months after an endometrial resection combined with a laparoscopy to exclude concomitant ovarian tumor and/or other extra-uterine disease. The patient underwent a follow-up of 3 months interval with endometrial sampling by hysteroscopy.
The recurrence rate and the pregnancy rate after fertility sparing treatment.
We identified 9 patients with EIN (50%), 7 patients with G1EC (38.9%), 1 with combined histology (5.5%), and 1 with G2EC (5.5%). After a median follow-up of 40.7 months, 12 patients conserved their uterus (66.7%), and 8 (53.3%) patients were pregnant with a total of 14 pregnancies among those who tried to become pregnant. We observed a complete response rate in 12 patients (66.7%) but 3 of these patients relapsed (25%). We also found a stable disease in 6 patients (33.3%).
Compared with other fertility sparing treatments, GnRH agonist after surgery is an effective fertility-sparing strategy for women with EIN and/or G1EC. We recommend hysterectomy once a family has been completed even if the literature does not clearly lead to radical surgery.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>30211167</pmid><doi>10.3389/fmed.2018.00240</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 2296-858X |
ispartof | Frontiers in medicine, 2018-08, Vol.5, p.240-240 |
issn | 2296-858X 2296-858X |
language | eng |
recordid | cdi_doaj_primary_oai_doaj_org_article_01e049bf6ed2474aa153cf0e4d4f874a |
source | PubMed Central Free |
subjects | atypical endometrial hyperplasia conservative treatment endometrial adenocarcinoma fertility-sparing GnRH agonist Medicine |
title | Fertility Sparing Treatment in Patients With Early Stage Endometrial Cancer, Using a Combination of Surgery and GnRH Agonist: A Monocentric Retrospective Study and Review of the Literature |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T05%3A04%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fertility%20Sparing%20Treatment%20in%20Patients%20With%20Early%20Stage%20Endometrial%20Cancer,%20Using%20a%20Combination%20of%20Surgery%20and%20GnRH%20Agonist:%20A%20Monocentric%20Retrospective%20Study%20and%20Review%20of%20the%20Literature&rft.jtitle=Frontiers%20in%20medicine&rft.au=Tock,%20St%C3%A9phanie&rft.date=2018-08-27&rft.volume=5&rft.spage=240&rft.epage=240&rft.pages=240-240&rft.issn=2296-858X&rft.eissn=2296-858X&rft_id=info:doi/10.3389/fmed.2018.00240&rft_dat=%3Cproquest_doaj_%3E2103675073%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c459t-b9e5df718624b26712cf0f5b85e78779ec7ff6987656485b851d320511358ba23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2103675073&rft_id=info:pmid/30211167&rfr_iscdi=true |